Thomas Enzler

4.0k total citations
39 papers, 1.4k citations indexed

About

Thomas Enzler is a scholar working on Oncology, Immunology and Surgery. According to data from OpenAlex, Thomas Enzler has authored 39 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 16 papers in Immunology and 8 papers in Surgery. Recurrent topics in Thomas Enzler's work include Pancreatic and Hepatic Oncology Research (10 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers). Thomas Enzler is often cited by papers focused on Pancreatic and Hepatic Oncology Research (10 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers). Thomas Enzler collaborates with scholars based in United States, Switzerland and Japan. Thomas Enzler's co-authors include Michael Karin, Thomas J. Kipps, Anthony P. James, Ned Mantei, Giorgio Semenza, Marco Villa, Hans Wacker, Werner Boll, Walter Hunziker and Dennis C. Otero and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Thomas Enzler

37 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Enzler United States 16 605 424 342 224 208 39 1.4k
Guillaume Meurice France 17 535 0.9× 732 1.7× 552 1.6× 196 0.9× 318 1.5× 34 1.7k
Laura Patrussi Italy 21 737 1.2× 637 1.5× 297 0.9× 179 0.8× 76 0.4× 46 1.5k
Stephen B. Gauld United States 21 1.2k 2.1× 361 0.9× 296 0.9× 174 0.8× 69 0.3× 40 1.8k
Makoto Yoshimitsu Japan 23 633 1.0× 567 1.3× 429 1.3× 124 0.6× 122 0.6× 102 1.7k
James D. Lord United States 21 1.0k 1.7× 536 1.3× 633 1.9× 271 1.2× 132 0.6× 40 1.8k
Sylvie Giuriato France 21 419 0.7× 1.3k 3.0× 388 1.1× 140 0.6× 299 1.4× 35 2.2k
Yaoyu E. Wang United States 21 331 0.5× 854 2.0× 368 1.1× 112 0.5× 284 1.4× 35 1.6k
Marat Alimzhanov United States 18 1.7k 2.8× 656 1.5× 465 1.4× 97 0.4× 232 1.1× 41 2.4k
Carolyn A. de Graaf Australia 20 427 0.7× 1.1k 2.6× 208 0.6× 135 0.6× 158 0.8× 32 1.9k
David Klinkebiel United States 18 320 0.5× 691 1.6× 258 0.8× 96 0.4× 163 0.8× 35 1.1k

Countries citing papers authored by Thomas Enzler

Since Specialization
Citations

This map shows the geographic impact of Thomas Enzler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Enzler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Enzler more than expected).

Fields of papers citing papers by Thomas Enzler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Enzler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Enzler. The network helps show where Thomas Enzler may publish in the future.

Co-authorship network of co-authors of Thomas Enzler

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Enzler. A scholar is included among the top collaborators of Thomas Enzler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Enzler. Thomas Enzler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chandana, Sreenivasa R, Ana Ruiz‐Casado, Andrew L. Coveler, et al.. (2025). 2223P First-line (1L) AZD0171 + durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): Phase II study results. Annals of Oncology. 36. S1150–S1151.
2.
Wang, Tianyi, Brian D. Griffith, Valerie Gunchick, et al.. (2025). Perioperative versus adjuvant therapy in resectable pancreas cancer.. Journal of Clinical Oncology. 43(4_suppl). 703–703.
3.
Enzler, Thomas & Timothy L. Frankel. (2025). Pancreatic cancer precursor lesions – Can immunotherapy prevent progression into pancreatic ductal adenocarcinoma?. Cancer Letters. 619. 217662–217662. 4 indexed citations
4.
Sahai, Vaibhav, Kent A. Griffith, David B. Zhen, et al.. (2024). Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04).. Journal of Clinical Oncology. 42(16_suppl). 4116–4116. 2 indexed citations
5.
Enzler, Thomas, Anna Nguyen, Jamal Misleh, et al.. (2024). A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma. European Journal of Cancer. 201. 113950–113950. 2 indexed citations
6.
Enzler, Thomas, Jiaqi Shi, Brian D. Griffith, et al.. (2024). A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions. International Journal of Molecular Sciences. 25(5). 2953–2953. 2 indexed citations
7.
Sahai, Vaibhav, Kent A. Griffith, Bruce Lin, et al.. (2024). BilT03: Phase 1b/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer. Med. 6(4). 100547–100547. 2 indexed citations
8.
Dayyani, Farshid, Marina Baretti, Sunyoung S. Lee, et al.. (2024). A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma.. Journal of Clinical Oncology. 42(3_suppl). TPS577–TPS577. 1 indexed citations
9.
Griffith, Kent A., David B. Zhen, Chandan Kumar‐Sinha, et al.. (2023). Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04). Clinical Cancer Research. 29(13). 2394–2400. 18 indexed citations
10.
Lopez, Adriana T., Robyn D. Gartrell, Kimberly M. Komatsubara, et al.. (2018). The Role of Oncolytic Viruses in the Treatment of Melanoma. Current Oncology Reports. 20(10). 80–80. 37 indexed citations
11.
Enzler, Thomas & Tito Fojo. (2017). Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors. Seminars in Oncology. 44(2). 141–156. 15 indexed citations
12.
Caballero‐Franco, Celia, Mónica Gumá, Min‐Kyung Choo, et al.. (2016). Epithelial Control of Gut-Associated Lymphoid Tissue Formation through p38α-Dependent Restraint of NF-κB Signaling. The Journal of Immunology. 196(5). 2368–2376. 5 indexed citations
13.
Taverna, Josephine A., Hani M. Babiker, Seongseok Yun, et al.. (2014). The great masquerader of malignancy: chronic intestinal pseudo-obstruction. Biomarker Research. 2(1). 23–23. 14 indexed citations
14.
Enzler, Thomas, Yasuyo Sano, Min‐Kyung Choo, et al.. (2011). Cell-Selective Inhibition of NF-κB Signaling Improves Therapeutic Index in a Melanoma Chemotherapy Model. Cancer Discovery. 1(6). 496–507. 30 indexed citations
15.
Enzler, Thomas, Xing Chang, Valeria Facchinetti, et al.. (2009). MEKK1 Binds HECT E3 Ligase Itch by Its Amino-Terminal RING Motif to Regulate Th2 Cytokine Gene Expression. The Journal of Immunology. 183(6). 3831–3838. 24 indexed citations
16.
Enzler, Thomas, Giuseppina Bonizzi, Gregg J. Silverman, et al.. (2006). Alternative and Classical NF-κB Signaling Retain Autoreactive B Cells in the Splenic Marginal Zone and Result in Lupus-like Disease. Immunity. 25(3). 403–415. 141 indexed citations
17.
Gallagher, Ewen, Thomas Enzler, Atsushi Matsuzawa, et al.. (2006). Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production. Nature Immunology. 8(1). 57–63. 85 indexed citations
18.
Enzler, Thomas, Silke Gillessen, John Manis, et al.. (2003). Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer. The Journal of Experimental Medicine. 197(9). 1213–1219. 145 indexed citations
19.
Mueller, Nicolas J., Peter W. Schiller, Norikazu Shimizu, et al.. (2002). Factor VII Deficiency and a Copper Metabolism Disorder in a Patient with Klippel-Trenaunay Syndrome. Dermatology. 204(3). 244–247. 4 indexed citations
20.
Enzler, Thomas, Markus Glatzel, & Marco Maggiorini. (2000). Eosinophilie und Polyneuropathie nach perkutaner transluminaler Koronarangioplastie. DMW - Deutsche Medizinische Wochenschrift. 125(30). 903–905. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guillaume Meurice Breakdown of academic impact, for papers by Laura Patrussi Breakdown of academic impact, for papers by Stephen B. Gauld Breakdown of academic impact, for papers by Makoto Yoshimitsu Breakdown of academic impact, for papers by James D. Lord Breakdown of academic impact, for papers by Sylvie Giuriato Breakdown of academic impact, for papers by Yaoyu E. Wang Breakdown of academic impact, for papers by Marat Alimzhanov Breakdown of academic impact, for papers by Carolyn A. de Graaf Breakdown of academic impact, for papers by David Klinkebiel
Rankless by CCL
2026